Idorsia's CEO Lasted Nine Months. Now the Founder Is Back.

That plan is now missing a pilot.

Idorsia completed a major debt restructuring in early 2025, and an upsized share offering in October 2025 extended its cash runway into 2028. In other words, the company has enough money to survive, but not enough to waste time figuring out who's in charge. Every quarter of leadership uncertainty is a quarter where execution slows, partnerships stall, and investors get nervous.

The stock reflects that anxiety. Idorsia's daily volatility has averaged a stomach-churning 7.57% over the past week, and the shares are classified as "very high risk" by analysts. For context, that's the kind of volatility you'd normally associate with a meme stock, not a company trying to commercialize real medicines.

The QUVIVIQ Lifeline

If there's one bright spot keeping Idorsia alive, it's QUVIVIQ (daridorexant), their insomnia drug. Think of it as the company's golden goose: the one product generating enough revenue to justify the entire operation.

QUVIVIQ sales more than doubled in 2025, reaching CHF 134 million globally. That's up from just CHF 61 million the year before. Europe has been the real engine of growth. The company is projecting roughly 50% growth in 2026, aiming for around CHF 200 million in sales.

The U.S. market, though, has been trickier. Idorsia slashed its American salesforce down to just 20 virtual reps at the start of 2025. It's a lean approach that's held sales roughly flat stateside.

Idorsia is also running a Phase 2 study for daridorexant in pediatric insomnia, with results expected in Q2 2026. It's the only drug of its type in development for kids, which could be a meaningful differentiator if the data cooperates.

What Else Is in the Medicine Cabinet?

Beyond QUVIVIQ, Idorsia has a couple of interesting irons in the fire.

TRYVIO/JERAYGO (aprocitentan) is their hypertension drug that targets a mechanism no other treatment has addressed in decades. It's already been included in the ACC/AHA hypertension guidelines, and a regulatory requirement called REMS (essentially extra safety monitoring) was removed in the first half of 2025, making it easier to prescribe. But the company hasn't included TRYVIO revenue in its 2026 guidance because commercialization depends on finding a partner, and those talks are still ongoing.

Then there's lucerastat, a potential first-in-class oral therapy for Fabry disease, a rare genetic disorder that currently relies on IV infusions or expensive enzyme replacement therapies. It's in a Phase 3 registration study with FDA alignment. If it works, it could be transformative for patients who don't have a convenient pill-based option today.

The company is also dabbling in immunology with a CCR6 antagonist being tested in psoriasis. That's early stage, but it signals ambition beyond insomnia and rare disease.

The Founder's Dilemma

Jean-Paul Clozel is a biotech legend in Swiss circles. He co-founded Actelion with his wife Martine (who still serves as Idorsia's Chief Scientific Officer), sold it to Johnson & Johnson for $30 billion, and then launched Idorsia from the assets J&J didn't want. The man doesn't lack for vision or track record.

But there's a reason founders sometimes struggle in turnaround mode. Building a company from scratch and rescuing one from financial distress require different skill sets. It's the difference between cooking a meal from a well-stocked kitchen and salvaging dinner after someone burned the main course.

Clozel stepped away from the CEO role in 2024, presumably because the Board wanted someone with fresh operational energy. Now he's back, and the question is whether this is a steady hand on the wheel or a sign that nobody else wants to drive.

What Happens Next

Idorsia's Annual General Meeting is set for May 6, 2026, where the Board plans to propose new independent directors. That could signal a broader governance refresh, or it could just be housekeeping. Either way, investors will be watching closely.

The more pressing question: can Idorsia find a permanent CEO who sticks? The company's turnaround hinges on flawless execution over the next 18 months. QUVIVIQ needs to keep growing. The cash needs to last. Potential partners for TRYVIO need to sign on the dotted line. And the pipeline has to deliver clinical data that justifies the company's existence as an independent entity.

All of that is hard enough with stable leadership. With a revolving door at the top, it's like trying to run a marathon while swapping out your shoes every few miles. Not impossible, but definitely not ideal.

The €2.3 Billion Bet That Hearing Aids Are the Next Big Thing in MedTech

Amplifon just dropped €2.3 billion to buy the company that makes the hearing aids it sells, creating a vertically integrated giant in one of medtech's fastest-growing markets. The deal reshapes an entire industry, and the competition should be worried.